The population that seeks preventive campaigns is not the main risk group for the disease. This fact explains the low number of lesions and the lack of cancer detection.
OBJECTIVE: To evaluate the efficacy and safety of Venlafaxine for the control of vestibular migraine (VM). METHODS: This is a systematic review of randomized clinical trials. The following databases were searched: PUBMED (1966-2021), EMBASE (1974-2021) and CENTRAL (Cochrane Library-2021). There was no geographic and period limitation in the survey. Data extraction and study quality assessment were carried out by two independent researchers. RESULTS: The search strategy identified 47 studies, of which 2 were included in this review, as they met the inclusion and exclusion criteria. Both evaluated the efficacy of venlafaxine in vestibular migraine, comparing the results with other drugs. The first study (2017) compared the effect of venlafaxine with flunarizine and valproic acid, while the second study (2015) compared the efficacy of venlafaxine with propranolol. Both showed improvement of vestibular symptoms in all groups evaluated, but only the groups submitted to treatment with venlafaxine showed a significant change in the emotional DHI (Dizziness Handicap Inventory) score and improvement in depressive symptoms. CONCLUSIONS: Although venlafaxine appears to have promising results, there is currently a scarcity of studies that allow currently to assess the efficacy and safety of the drug for the treatment of vestibular migraine. The evidence is quite limited, the number of studies and patients evaluated reduced, and it is recommended to conduct new quality randomized clinical trials to elucidate the issue.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.